A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen

Paul Ruff(University of the Witwatersrand), Daniel Vorobiof(Morningside College), J. P. Jordaan(Addington Hospital), Georgia Demetriou(University of the Witwatersrand), S. D. Moodley(University of the Witwatersrand), Adam Nosworthy(University of the Witwatersrand), I. D. Werner(Groote Schuur Hospital), Johann Raats, Lesley Burgess(Tygerberg Hospital)
Cancer Chemotherapy and Pharmacology
February 24, 2009
Cited by 83

Abstract


Related Papers

No related papers found

Powered by citation graph analysis